Limited time75% off all plans
Get the app

Peripheral vascular disease therapies

Peripheral vascular disease therapies

Peripheral vascular disease therapies

On this page

PVD Overview - Taming the Pipes

  • Pathophysiology: Atherosclerosis narrows peripheral arteries, primarily in the lower extremities, leading to ↓ blood flow.
  • Presentation:
    • Intermittent Claudication: Muscle pain/cramping with exertion, relieved by rest.
    • Critical Limb Ischemia (CLI): Rest pain, non-healing ulcers, or gangrene. Requires urgent intervention.
  • Diagnosis:
    • Ankle-Brachial Index (ABI): Key non-invasive test.
      • Normal: 1.0-1.4
      • PVD: <0.9
      • Severe: <0.4

Peripheral Artery Disease: Narrowed and Blocked Artery

Cilostazol, a phosphodiesterase inhibitor, is a key drug for symptomatic relief of claudication but is contraindicated in heart failure.

Antiplatelets & Statins - Plaque Patrol

  • Aspirin
    • Irreversibly inhibits COX-1 & COX-2, leading to ↓ Thromboxane A₂ (TXA₂) and reduced platelet aggregation.
    • Dose: 81-325 mg daily.
  • Clopidogrel (Plavix)
    • Irreversibly blocks the P2Y₁₂ ADP receptor on platelets, preventing activation of GPIIb/IIIa receptors.
    • Often used in dual antiplatelet therapy (DAPT) with aspirin, especially post-stenting.
  • Cilostazol
    • Phosphodiesterase III inhibitor; ↑ cAMP causes vasodilation and reversible inhibition of platelet aggregation.
    • Primary indication: intermittent claudication.
  • Statins (e.g., Atorvastatin)
    • HMG-CoA reductase inhibitors.
    • ↓ LDL, stabilize atherosclerotic plaques, and have pleiotropic anti-inflammatory effects.

High-Yield: Cilostazol is contraindicated in any patient with heart failure due to increased mortality risk.

Statins: Anti-atherosclerotic mechanisms

Claudication Agents - Walking Tall

  • Cilostazol

    • Mechanism: Phosphodiesterase-3 (PDE-3) inhibitor. ↑cAMP in platelets & vascular smooth muscle.
    • Effects: Potent arterial vasodilation (esp. femoral) & reversible inhibition of platelet aggregation.
    • Primary use: Symptomatic management of intermittent claudication to improve walking distance.
    • 📌 Cilo-STAY-zol helps you STAY on the walking trail.
  • Pentoxifylline

    • Mechanism: A methylxanthine derivative; improves erythrocyte flexibility and decreases blood viscosity.
    • Efficacy: Generally considered less effective than cilostazol; not a primary therapy.

Cilostazol: Mechanism of Action in Peripheral Artery Disease

Contraindication: Cilostazol is contraindicated in patients with heart failure of any severity due to an observed ↑mortality with other PDE-3 inhibitors in this population.

Treatment Algorithm - The Game Plan

  • Foundation: Lifestyle modification (smoking cessation, graded exercise) & aggressive risk factor control (statins, BP/glucose management).
  • Symptomatic Relief: Add specific pharmacotherapy for claudication.

Peripheral vascular disease and ischemia

Cilostazol, a phosphodiesterase inhibitor, not only improves claudication symptoms but also causes arterial vasodilation. However, it is contraindicated in heart failure due to arrhythmogenic potential.

  • Cilostazol, a phosphodiesterase-3 inhibitor, is a primary therapy for intermittent claudication, offering vasodilation and antiplatelet effects.
  • Aspirin or clopidogrel are crucial for secondary prevention of cardiovascular events in all patients with PAD.
  • Statins are essential to manage the underlying atherosclerosis and reduce cardiovascular risk, regardless of cholesterol levels.
  • ACE inhibitors or ARBs manage co-existing hypertension and may have direct vascular benefits.

Continue reading on Oncourse

Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.

CONTINUE READING — FREE

or get the app

Rezzy — Oncourse's AI Study Mate

Have doubts about this lesson?

Ask Rezzy, your AI Study Mate, to explain anything you didn't understand

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

START FOR FREE